JP2000169332A - Sebum secretion inhibitor and skin cosmetic - Google Patents
Sebum secretion inhibitor and skin cosmeticInfo
- Publication number
- JP2000169332A JP2000169332A JP10349723A JP34972398A JP2000169332A JP 2000169332 A JP2000169332 A JP 2000169332A JP 10349723 A JP10349723 A JP 10349723A JP 34972398 A JP34972398 A JP 34972398A JP 2000169332 A JP2000169332 A JP 2000169332A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- plant
- skin
- azami
- sebum secretion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は、皮脂分泌抑制剤に
関し、さらに詳しくは、皮脂腺の活動を抑制すること
で、皮脂腺内での炎症の発生を未然に防ぎ炎症によるニ
キビ痕を形成させないでニキビを治療したり、皮脂によ
る皮膚のてかりや化粧くずれを防止する皮脂分泌抑制剤
に関する。また該剤を含有する皮膚化粧料に関する。TECHNICAL FIELD The present invention relates to a sebum secretion inhibitor, and more particularly to an agent for inhibiting acne activity by suppressing sebaceous gland activity, thereby preventing the occurrence of inflammation in sebaceous glands without forming acne scars due to inflammation. The present invention relates to a sebum secretion inhibitor which treats skin and prevents skin irritations and makeup loss due to sebum. It also relates to a skin cosmetic containing the agent.
【０００２】[0002]
【従来の技術および発明が解決しようとする課題】皮膚
は、物質の生体内への侵入と生体内部からの水分の過剰
蒸散を防ぐ、バリア機能を持っており、その最も外側に
皮脂腺から分泌される皮脂と汗腺から分泌される汗が混
ざりあった皮脂膜がある。したがって、皮脂は皮膚の恒
常性維持に重要な物質である。2. Description of the Related Art Skin has a barrier function to prevent substances from entering a living body and excessive evaporation of water from the living body, and is secreted from the sebaceous glands on the outermost side. There is a sebaceous membrane in which sebum and sweat secreted from sweat glands are mixed. Therefore, sebum is an important substance for maintaining skin homeostasis.
【０００３】現在では食生活の欧米化やストレスによる
内分泌系（性ホルモン）バランスの異常により、皮脂が
過剰に合成される傾向にある。そして、皮脂腺の皮膚表
面への開口部である毛穴が、垢や空気中の埃等で塞がれ
ると、皮膚内で皮脂が塊となり周辺の細胞に圧力を与え
違和感を覚えるようになる。この状態がコメドと呼ばれ
るニキビの初期段階であり、皮膚が突っ張るような感じ
を与える。次に、毛穴からアクネ菌等の細菌が侵入し炎
症を起こした状態（赤ニキビ）となり、さらに炎症が進
み皮脂腺内に膿が溜まった状態（黄ニキビ）とニキビは
進行する。このように赤および黄ニキビまで進行する
と、炎症が治まっても毛穴周辺の表皮は、過増殖を起こ
し、いわゆるニキビ痕を形成する。したがって、コメド
を形成させない、または発達させないことが、赤および
黄ニキビといった皮膚科学上好ましくない炎症の発生を
抑制するとともに、ニキビ痕といった美容上も好ましく
ない状態を防止するためにも必要である。また、皮脂の
過剰な分泌は、皮膚のてかりやファンデーションなどの
メイク料がよれる原因となり、美容上好ましくない。At present, sebum tends to be excessively synthesized due to the westernization of dietary habits and abnormalities in the endocrine system (sex hormone) due to stress. Then, when the pores, which are the openings of the sebaceous glands to the skin surface, are closed with dirt or dust in the air, sebum forms a lump in the skin, exerting pressure on the surrounding cells and giving a sense of incongruity. This state is the initial stage of acne called comed, which gives the skin a feeling of strain. Next, bacteria such as acne bacteria enter the pores and become inflamed (red acne). Inflammation further progresses and pus accumulates in the sebaceous glands (yellow acne), and acne progresses. When the red and yellow acne progresses in this way, the epidermis around the pores overgrows even after the inflammation subsides, forming so-called acne scars. Therefore, it is necessary not to form or develop comeds in order to suppress the occurrence of dermatologically unfavorable inflammation such as red and yellow acne and also to prevent cosmetically unfavorable conditions such as acne scars. In addition, excessive secretion of sebum is unfavorable in terms of beauty because it causes the makeup ingredients such as skin shine and foundation.
【０００４】そして、これまでにコメドの形成および発
達を抑制する皮脂分泌抑制の特効薬として、ビタミンＡ
酸が医薬品として米国で用いられているが、副作用の問
題から我国では用いることが出来ない。したがって、副
作用が少なく安全でコメドの形成および発達を抑制する
ための皮脂腺活動を抑制する物質で充分満足するに足り
るものはなかった。[0004] Vitamin A has been hitherto used as a specific medicine for inhibiting sebum secretion, which suppresses comed formation and development.
Acids are used in the United States as pharmaceuticals, but cannot be used in Japan due to side effects. Accordingly, there has been no satisfactory substance that suppresses sebaceous gland activity for suppressing comed formation and development with few side effects.
【０００５】本発明の目的は、安全な皮脂分泌抑制剤を
提供することにあり、さらにはコメドの形成および発達
を防止するために皮脂腺活動を抑制する皮脂分泌抑制剤
および該剤を含有することを特徴とする皮膚化粧料を提
供することにある。[0005] It is an object of the present invention to provide a safe sebum secretion inhibitor, and to further contain a sebum secretion inhibitor that suppresses sebaceous gland activity in order to prevent the formation and development of comedo. It is to provide a skin cosmetic characterized by the following.
【０００６】[0006]
【課題を解決するための手段】本発明者等は、上記のよ
うな状況を鑑みて鋭意研究を行った結果、キク科のシリ
ブム・マリアヌムの抽出物がコメドモデルの皮脂腺に対
し効果に優れ、しかも安全性に優れることを確認して本
発明を完成するに至った。すなわち、本発明は、シリブ
ム・マリアヌム等キク科マリアアザミ属植物の抽出物を
含有することを特徴とする皮脂分泌抑制剤および該剤を
含有することを特徴とする皮膚化粧料にある。Means for Solving the Problems The present inventors have conducted intensive studies in view of the above situation, and as a result, it has been found that an extract of Syllabium marianum of the Asteraceae family has an excellent effect on the sebaceous glands of the comedo model, In addition, the inventors have confirmed that the present invention is excellent in safety, and have completed the present invention. That is, the present invention resides in a sebum secretion inhibitor containing an extract of a plant of the family Asteraceae, such as Syllabum marianeum, and a skin cosmetic containing the agent.
【０００７】[0007]
【発明の実施の形態】以下、本発明の実施の形態を詳述
する。Embodiments of the present invention will be described below in detail.
【０００８】本発明に用いるキク科マリアアザミ属の植
物としては、シリブム・マリアヌム（Silybum Marianu
m;マリアアザミ、オオアザミまたはオオヒレアザミと呼
ばれる。）が著名であり、この抽出物は公知であり、そ
の活性物質としてシリマリン、シリビン、シリクリスチ
ンおよびシリジアニン等が単独または混合物として存在
する。抽出方法は上記植物の全草または葉、茎、果実等
個別にしたものより、メタノール、エタノールその他の
低級アルコール、１，３ブチレングリコール、プロピレ
ングリコール等の低級多価アルコール、もしくはアセト
ン、ベンゼン、塩化メチレン、酢酸エチル、酢酸ブチ
ル、クロロホルム、エチルエーテル等の中間極性を持つ
有機溶媒等またはこれらの混液にて抽出を行えばよく、
水が混入していてもよい。そして、このシリブム・マリ
アヌムの抽出物、特にシリマリンは酸化防止剤として広
く知られており、また、乾癬およびアトピー性皮膚炎治
療製剤（特開平５−２８６８６４号公報）やバクテリア
抽出物との組み合わせで皮膚および／または髪の光保護
等のための局所使用用組成物（特開平８−３０１５号公
報）等に応用されている。しかしながら、皮脂腺活動を
抑制する効果は、まったく知られておらず類推も不可能
であった。[0008] The plants of the genus Maria Thistle of the family Asteraceae used in the present invention include Silybum Marianu.
m; also called Maria thistle, Milk thistle or Greater thistle. ) Is well-known, and this extract is known, and its active substances, such as silymarin, silybin, silychristin, and silidianin, exist alone or as a mixture. The extraction method is as follows. From the whole plant or leaves, stems, fruits, etc. of the above plants, methanol, ethanol or other lower alcohols, lower polyhydric alcohols such as 1,3 butylene glycol, propylene glycol, or acetone, benzene, chloride Methylene, ethyl acetate, butyl acetate, chloroform, organic solvents having an intermediate polarity such as ethyl ether or the like or a mixture thereof may be extracted,
Water may be mixed. The extract of C. sylivum marianium, particularly silymarin, is widely known as an antioxidant, and is used in combination with a psoriasis and atopic dermatitis therapeutic preparation (Japanese Patent Application Laid-Open No. 5-286864) and a bacterial extract. It has been applied to a composition for topical use for protecting the skin and / or hair from light (JP-A-8-3015). However, the effect of suppressing sebaceous gland activity was not known at all and could not be analogized.
【０００９】本発明のキク科マリアアザミ属植物の抽出
物の配合量は、皮脂分泌抑制剤の総量を基準として、乾
燥物換算で０．０００１〜１０．０重量％が好ましく、
さらに好ましくは０．００１〜１．０重量％である。
０．０００１重量％未満の配合量では、本発明の目的と
する効果が十分でない場合があり、一方、上限（１０．
０重量％）を越えて配合してもその増加分に見合った効
果の向上がない場合があり、好ましくない。The amount of the extract of the plant belonging to the genus Maria Thistle of the present invention is preferably 0.0001 to 10.0% by weight in terms of dry matter, based on the total amount of the sebum secretion inhibitor.
More preferably, it is 0.001 to 1.0% by weight.
If the amount is less than 0.0001% by weight, the intended effect of the present invention may not be sufficient, while the upper limit (10.
(0% by weight), the effect may not be improved in proportion to the increase, which is not preferable.
【００１０】本発明の皮脂分泌抑制剤は、化粧料、皮膚
外用剤および入浴剤等に適用でき、剤型的には例えばロ
−ション、乳液、クリ−ム、パック、顆粒、粉末等、種
々のものとすることができる。また、本発明において、
皮膚とは頭皮を含むものであり、頭皮に適用した場合に
は、余分な皮脂を抑制することにより更なる効果とし
て、ふけ防止や、毛穴の詰まり等を防ぎ育毛・養毛効果
に寄与することができる。The sebum secretion inhibitor of the present invention can be applied to cosmetics, external preparations for the skin, bath preparations, etc., and in dosage form, for example, lotions, emulsions, creams, packs, granules, powders, etc. It can be. In the present invention,
The skin includes the scalp, and when applied to the scalp, suppresses excess sebum to further prevent dandruff and prevent clogging of pores, contributing to hair growth and hair growth effects. Can be.
【００１１】本発明の皮脂分泌抑制剤には、化粧品、医
薬部外品、医薬品等に一般に用いられる色素、香料、防
腐剤、界面活性剤、顔料、抗酸化剤等を本発明の目的を
達成する範囲内で適宜配合することができる。The sebum secretion inhibitor of the present invention includes pigments, fragrances, preservatives, surfactants, pigments, antioxidants, etc. commonly used in cosmetics, quasi-drugs, pharmaceuticals and the like to achieve the object of the present invention. It can be appropriately compounded within the range specified.
【００１２】[0012]
【実施例】以下、実施例及び比較例に基づいて本発明を
詳説する。The present invention will be described below in detail with reference to examples and comparative examples.
【００１３】実施例１〜６および比較例１、２ 本発明をコメドモデルのライノマウスに適用したときの
皮脂腺直径に対する効果を次の試験方法により調べた。Examples 1 to 6 and Comparative Examples 1 and 2 The effect on the sebaceous gland diameter when the present invention was applied to a comedo model rhino mouse was examined by the following test method.
【００１４】１．本実施例および比較例で使用した実験
動物 試験開始時１８週齢のライノマウス１群４匹を用いた。1. Experimental Animals Used in the Examples and Comparative Examples Four groups of 18-week-old rhino mice at the start of the test were used.
【００１５】２．皮脂腺直径の測定 ２−１．試料 シリブム・マリアヌム果実を粉砕し３倍量のエタノール
にて２昼夜抽出し、減圧乾燥したものを用いた。エタノ
ール（基剤）に、得られたシリブム・マリアヌム抽出乾
燥物（以下、抽出乾燥物と略記する。）を、０．００
１、０．０１、０．１、１．０および２．０％を溶解し
試料を調製した。そして対照として基剤のみと、基剤に
ニキビ治療薬として知られているレチノイン酸（all-tr
ans,シグマ社製）０．０２重量％を配合したものを用い
た。2. Measurement of sebaceous gland diameter 2-1. Sample The fruit of Syribum marianum was pulverized, extracted with three times the amount of ethanol for two days and nights, and dried under reduced pressure. In ethanol (base), the obtained dried extract of Sylibum marianum (hereinafter abbreviated as “extracted dry product”) was added to 0.00.
Samples were prepared by dissolving 1, 0.01, 0.1, 1.0 and 2.0%. As a control, only the base was used, and retinoic acid (all-tr
ans, Sigma) 0.02% by weight.
【００１６】２−２．実験方法 各試料０．０５ｍｌをライノマウスの背部皮膚（２×４
ｃｍ）に１日１回、一週間に５回の頻度で３週間連続の
塗布を行った。その後、試料の最終塗布から３日目にマ
ウスを屠殺し、背部皮膚を採取（２×４ｃｍ）した。こ
の皮膚を０．５％酢酸水溶液に１８時間（４℃）浸し、
表皮を剥離した。そして、表皮側を下にしてスライドガ
ラスに貼りつけ、アルコール・キシレン系で脱水を行い
バルサムで封入した。この標本１枚につき５視野ずつ顕
微鏡下（２５倍）での写真を撮影し、１視野で１０個の
皮脂腺について直径（長径と短径の平均値）をノギスで
測定した。この直径は皮脂腺の大きさを示し、皮脂腺の
活動が活発であると皮脂腺内に貯留する皮脂が多くなる
ため直径が大きくなり、逆に皮脂腺の活動が抑制される
と貯留した皮脂が減少するため直径が小さくなる。ま
た、直径の値は同倍率で撮影したミクロメータを用いて
換算した値で示した。2-2. Experimental method 0.05 ml of each sample was applied to the back skin of rhino mice (2 × 4
cm) once a day and five times a week for three consecutive weeks. The mice were then sacrificed 3 days after the final application of the samples and the back skin was harvested (2 × 4 cm). This skin is immersed in a 0.5% acetic acid aqueous solution for 18 hours (4 ° C.)
The epidermis was peeled off. Then, it was attached to a slide glass with the epidermis side down, dehydrated with an alcohol-xylene system, and sealed with balsam. Five specimens were photographed under a microscope (25 times) for each specimen, and the diameter (average value of major axis and minor axis) of 10 sebaceous glands in one visual field was measured with a caliper. This diameter indicates the size of the sebaceous gland.If the activity of the sebaceous gland is active, the diameter increases because the sebum stored in the sebaceous gland increases, and conversely, if the activity of the sebaceous gland is suppressed, the stored sebum decreases. The diameter becomes smaller. Further, the value of the diameter was shown as a value converted using a micrometer photographed at the same magnification.
【００１７】各試料の塗布によるライノマウス皮脂腺直
径への効果を表１に示す。Table 1 shows the effect on rhino mouse sebaceous gland diameter by application of each sample.
【００１８】[0018]
【表１】 [Table 1]
【００１９】表１記載の通り、実施例１〜５は、比較例
１と比較して明らかに、濃度依存的に皮脂腺直径が小さ
くなったことが分かる。一方、実施例１〜５と比較例２
を比較すると、比較例２の方が有効であることが分か
る。しかし、皮膚表面の肉眼観察で、実施例１〜５はま
ったく皮膚表面に異常は認められなかったが、比較例２
では多数の落屑とともに炎症状態であると思われる紅斑
が認められ、荒れ肌状態が観察された。そして、荒れ肌
状態の指標である経皮水分蒸散量を測定すると２ｍｇ／
ｃｍ2／分と非常に高い値が観察され（正常値および実
施例１〜６は０．０２ｍｇ／ｃｍ2／分以下の値）、重
度な荒れ肌状態であることが分かった。したがって、本
発明は皮膚に重大な影響を与えることなく皮脂腺の活動
を抑制出来ることが分かった。As shown in Table 1, Examples 1 to 5 clearly show that the diameter of the sebaceous gland decreased in a concentration-dependent manner as compared with Comparative Example 1. On the other hand, Examples 1 to 5 and Comparative Example 2
By comparison, it can be seen that Comparative Example 2 is more effective. However, by visual observation of the skin surface, Examples 1 to 5 showed no abnormality on the skin surface, while Comparative Example 2
As a result, erythema which was considered to be an inflammatory condition was observed along with a large amount of desquamation, and a rough skin condition was observed. When the amount of transepidermal water loss, which is an index of the rough skin condition, is measured, 2 mg /
A very high value of cm 2 / min was observed (normal value and a value of 0.02 mg / cm 2 / min or less in Examples 1 to 6), indicating a severe rough skin condition. Therefore, it was found that the present invention can suppress the activity of the sebaceous glands without significantly affecting the skin.
【００２０】尚、経皮水分蒸散量は、連続発汗測定装置
ハイドログラフＡＭＵ−１００（ケイアンドエス社製）
を用いて次の通りに測定した。１平方センチメートルの
カプセルを皮膚に密着させ、カプセル内に窒素ガスを導
入（３００ミリリットル／分）し、カプセルに送り出す
前とカプセルから回収した後の窒素ガス中の水蒸気量を
測定した。この値の差から、１分あたり皮膚１平方セン
チメートルから蒸散する水分量（ミリグラム）を算出
し、経皮水分蒸散量とした。The amount of transepidermal water loss was measured using a continuous perspiration measuring device Hydrograph AMU-100 (manufactured by K & S).
Was measured as follows. A 1 cm 2 capsule was brought into close contact with the skin, nitrogen gas was introduced into the capsule (300 ml / min), and the amount of water vapor in the nitrogen gas was measured before being sent to the capsule and after being recovered from the capsule. From the difference between the values, the amount of water (milligram) evaporating from one square centimeter of skin per minute was calculated, and it was defined as the amount of transepidermal water evaporation.
【００２１】実施例６ 表２の組成のスキンローションを下記の調製法にしたが
って調製し、事前の聞き取り調査によりニキビができや
すいと回答した１０名の男女（男性５名，女性５名，１
９〜３２歳）の顔面頬部に抽出乾燥物１．０ｗｔ％配合
品（実施例６）を左に、無配合品（比較例３）を右に
（被検者には試料の詳細をふせたまま）２週間連続（１
日１回、入浴後）で塗り分けてもらい、実験終了時に左
右の使用感を表３の内容のアンケートで回答してもらっ
た。Example 6 A skin lotion having the composition shown in Table 2 was prepared according to the following preparation method, and 10 men and women (5 men, 5 women, 1
On the face cheeks (9-32 years old), extract 1.0% by weight of the extracted and dried product (Example 6) on the left and non-compounded product (Comparative Example 3) on the right (examine the details of the sample for the subject). 2 weeks in a row
(Once a day, after bathing), and the left and right feelings of use were answered by a questionnaire shown in Table 3 at the end of the experiment.
【００２２】[0022]
【表２】 [Table 2]
【００２３】調製法 Ｃ成分の抽出乾燥物をＢ成分に配合して、Ａ，Ｂ成分を
各々均一に溶解した後、Ａ成分とＢ成分を混合撹拌分散
し、次いで容器に充填する。使用時には内容物を均一に
振盪分散して使用する。Preparation Method The extracted and dried product of the component C is blended with the component B, and the components A and B are uniformly dissolved, and then the components A and B are mixed, stirred and dispersed, and then filled into a container. When used, the contents are shaken and dispersed uniformly.
【００２４】[0024]
【表３】 [Table 3]
【００２５】上記アンケートで、各項目の回答番号を点
数として、ＩおよびＩＩの項目では左の点数が各人にお
いて、右より２点以上小さい場合を著効、１点を効果あ
り、０点以下を効果なしとした。ＩＩＩについては回答
人数で示した。結果を表４に示す。In the above questionnaire, the answer number of each item is defined as a point, and in the items of I and II, when the score on the left is smaller than the right by two or more points in each person, the effect is significant, 1 point is effective, and 0 point or less No effect. For III, the number of respondents is shown. Table 4 shows the results.
【００２６】[0026]
【表４】 [Table 4]
【００２７】表４に示す通り本実施例は、ニキビに対す
る両項目ともに明らかな効果が認められ、しかも刺激が
ほとんど認められないことが明らかとなった。As shown in Table 4, in this example, it was found that both items had a clear effect on acne, and that little irritation was observed.
【００２８】[0028]
【発明の効果】以上記載のごとく、本発明は、皮脂腺の
活動を抑制することで、皮脂腺内での炎症の発生を未然
に防ぎ、さらには炎症によるニキビ痕を形成させないで
ニキビを治療することの可能な皮脂分泌抑制剤および皮
膚化粧料を提供することができる。As described above, the present invention suppresses the activity of sebaceous glands, thereby preventing the occurrence of inflammation in the sebaceous glands, and further treating acne without forming acne scars due to inflammation. It is possible to provide a sebum secretion inhibitor and a skin cosmetic which can be used.
Claims (3)
有することを特徴とする皮脂分泌抑制剤。1. A sebum secretion inhibitor comprising an extract of a plant belonging to the genus Maria Thistle of the family Asteraceae.
・マリアヌムである請求項１記載の皮脂分泌抑制剤。2. The sebum secretion inhibitor according to claim 1, wherein the plant of the genus Maria Thistle in the family Asteraceae is Syribum marianeum.
を含有することを特徴とする皮膚化粧料。3. A skin cosmetic comprising the sebum secretion inhibitor according to claim 1 or 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10349723A JP2000169332A (en) | 1998-12-09 | 1998-12-09 | Sebum secretion inhibitor and skin cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10349723A JP2000169332A (en) | 1998-12-09 | 1998-12-09 | Sebum secretion inhibitor and skin cosmetic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2000169332A true JP2000169332A (en) | 2000-06-20 |
Family
ID=18405674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10349723A Pending JP2000169332A (en) | 1998-12-09 | 1998-12-09 | Sebum secretion inhibitor and skin cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2000169332A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001288072A (en) * | 2000-02-04 | 2001-10-16 | Akira Sasaki | Bathing agent |
| JP2008530062A (en) * | 2005-02-11 | 2008-08-07 | グリーンファーマ | Use of silymarin and / or silymarin constituents as skin or hair pigmentation stimulants |
| US8022038B2 (en) | 2005-09-29 | 2011-09-20 | Fancl Corporation | Composition for acceleration of type I collagen production |
| JP2021506884A (en) * | 2017-12-20 | 2021-02-22 | ピエール、ファブレ、デルモ‐コスメティークＰｉｅｒｒｅ Ｆａｂｒｅ Ｄｅｒｍｏ−Ｃｏｓｍｅｔｉｑｕｅ | Retinoids and Silibum marianum (L.) Gaertn. Extract combination |
| RU2746724C2 (en) * | 2016-07-01 | 2021-04-19 | Пьер Фабр Дермо-Косметик | New extract of silybum marianum achenes and use thereof in dermatology and dermatological cosmetics |
| RU2794229C2 (en) * | 2017-12-20 | 2023-04-13 | Пьер Фабр Дермо-Косметик | Combination of retinoid and silybum marianum (l.) gaertn extract |
-
1998
- 1998-12-09 JP JP10349723A patent/JP2000169332A/en active Pending
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001288072A (en) * | 2000-02-04 | 2001-10-16 | Akira Sasaki | Bathing agent |
| JP2008530062A (en) * | 2005-02-11 | 2008-08-07 | グリーンファーマ | Use of silymarin and / or silymarin constituents as skin or hair pigmentation stimulants |
| US8569358B2 (en) | 2005-02-11 | 2013-10-29 | Greenpharma | Use of silymarin and/or constituents thereof as skin or hair pigmentation promoters |
| US8022038B2 (en) | 2005-09-29 | 2011-09-20 | Fancl Corporation | Composition for acceleration of type I collagen production |
| RU2746724C2 (en) * | 2016-07-01 | 2021-04-19 | Пьер Фабр Дермо-Косметик | New extract of silybum marianum achenes and use thereof in dermatology and dermatological cosmetics |
| US11285185B2 (en) | 2016-07-01 | 2022-03-29 | Pierre Fabre Dermo-Cosmetique | Methods for treating in dermatology and dermo-cosmetics by administering Silybum marianum achene extract |
| JP2021506884A (en) * | 2017-12-20 | 2021-02-22 | ピエール、ファブレ、デルモ‐コスメティークＰｉｅｒｒｅ Ｆａｂｒｅ Ｄｅｒｍｏ−Ｃｏｓｍｅｔｉｑｕｅ | Retinoids and Silibum marianum (L.) Gaertn. Extract combination |
| RU2794229C2 (en) * | 2017-12-20 | 2023-04-13 | Пьер Фабр Дермо-Косметик | Combination of retinoid and silybum marianum (l.) gaertn extract |
| US11690886B2 (en) | 2017-12-20 | 2023-07-04 | Pierre Fabre Dermo-Cosmetique | Combination of a retinoid and an extract of Silybum marianum (L.) gaertn |
| JP7404240B2 (en) | 2017-12-20 | 2023-12-25 | ピエール、ファブレ、デルモ‐コスメティーク | Retinoids and Siribum marianum (L.) Gaertn. combination of extracts of |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114306171B (en) | Topical skin composition and use thereof | |
| ES2702607T3 (en) | Cosmetic composition and hair growth retardation method | |
| KR100325317B1 (en) | Pharmaceutical and cosmetic antiacne formulations containing plant extracts (Krameria triandra or Mesua ferrea) | |
| KR20200035040A (en) | New cosmetic use of Nephelium rapaseum extract | |
| KR102142311B1 (en) | Skin external composition comprising tangeretin | |
| EP2691074A1 (en) | Composition based on camellia japonica and polygonum hydropiper for protecting the skin | |
| KR101917645B1 (en) | Cosmetic composition comprising saccharomyces ferment filtrate, asparagus officinalis stem extract and tussilago farfara flower extract | |
| US20040126351A1 (en) | Topical composition having natural skin anti-irritant ingredient and method of use | |
| JP2001187725A (en) | Stress preventive agent and skin care preparation containing the same | |
| KR102214985B1 (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| KR20210018388A (en) | Compositions for improving skin conditions comprising plant extracts or fractions thereof | |
| KR101418366B1 (en) | Composition containing bee venom and propolis for preventing or treating acne | |
| KR100638053B1 (en) | Cosmetic composition for abirritating skin containing extract of rumex crispus as active ingredient | |
| KR101034405B1 (en) | Antibiotic composition containing herbal medicine extracts | |
| KR20210090870A (en) | Cosmetic composition with excellent skin barrier using skin microbiome | |
| US8334001B2 (en) | Composition comprising mucilaginous polysaccharides derived from aloe barbadensis and method for obtaining same and use thereof | |
| JP2000169332A (en) | Sebum secretion inhibitor and skin cosmetic | |
| KR20230135528A (en) | Cosmetic compositions comprising astaxanthin, epidermal growth factor and mixed extracts of natural product as effective components | |
| HU211100B (en) | Cosmetic composition with skin regenerating effect, comprising active ingredients of vegetable origin | |
| KR101648466B1 (en) | Cosmetic composition for improving skin | |
| KR20100067700A (en) | Cosmetic compositions for skin care containing extract of tussilago farfara linne flower | |
| KR20220104655A (en) | Composition for treating acne containing nanoized bee pollen extract as an active ingredient | |
| KR100538078B1 (en) | Cosmetic Compositions Comprising Panax ginseng (C.A. MEY) Extract and Plant Extracts as Oriental Medicine for Preventing Skin Aging | |
| JP2019530655A (en) | Use of Arbutus unedo fruit extract as cosmetics | |
| KR101286140B1 (en) | Cosmetic composition for moisturizing and anti-irritation of skin containing polysaccharide from nelumbo nucifera rhizome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040701 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20040805 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20040806 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20051024 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051206 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060328 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060725 |